Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. - Wikidata - awgldk - TriplyDB

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

http://www.wikidata.org/entity/Q35156935

about

Harnessing the protective potential of HIV-1 neutralizing antibodies Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine Boosting vaccine efficacy the natural (killer) way Systems serology for evaluation of HIV vaccine trials.Survivors Remorse: antibody-mediated protection against HIV-1.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1 Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Developing a Successful HIV Vaccine.HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes.Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine The role of Fc receptors in HIV prevention and therapy.Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses.Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma.Antibodies as a source of anti-infective peptides: an update.Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections.Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice.Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Novel Concepts for HIV Vaccine Vector Design.Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors.

P2860

Q26766153-9C8F0B0E-C67B-4505-B5D2-1BC9617349E3 Q26782237-DC54EA3C-F714-4BF1-980E-E9E1ACD05674 Q26830360-01949BC9-9C49-4D16-A65F-B8AFE4796D58 Q28084474-B879FFCF-CDD4-440E-9B01-1CA618A0316E Q30238729-4941BD72-CA4F-445E-BF21-9B2AA9339CB8 Q30238730-B484325A-67E0-48B7-A75D-7FAB70AE81AF Q33821896-A03E9738-6602-4BFF-95B4-D5EFAF071A33 Q34540352-6B7B786E-4AD6-4AAF-926D-BD2D5AE82646 Q35913921-441C132E-BE12-48FD-A434-42A2DB061762 Q36008380-CB5A9A30-6D4D-4E62-868C-59C29F168FCF Q36071896-82794415-9D69-45EF-8092-281A6910AA5D Q36323975-2C7CC9C4-344D-456C-8E52-CF055972F811 Q36523998-A6D52002-A104-41E2-8DD0-A218F73BC30E Q36708266-6E73EB11-3C5E-45BF-AEAB-3619EA011595 Q37113972-6D1528A8-93A9-4343-993D-D7E0B80D09AC Q37261545-425A8A8D-D165-455E-BC6E-577845D21361 Q37399606-D517783B-1969-413C-B910-0B36341346C9 Q37497214-5ED20E19-3B89-4BC9-8E6B-96FBFACA9330 Q37523341-13E35FE3-D83C-4923-98C8-7082CC5D6AE3 Q37718399-50BB4E05-5586-413A-B4A2-36FD4A360102 Q38539513-1BB8FD05-E5D1-429F-B3EA-E06DC05EC170 Q38652858-400E911E-BDA9-4F0A-90B4-FAFC4737049E Q38717198-D7ADB6C8-DE1B-4EEF-869E-9ABECD9A1F26 Q38827936-4A0EAB67-1CE3-4624-8D57-FD0F00A858AB Q39189458-E23DF588-DBC9-4B74-B2D4-BCDE4BC062E5 Q39305961-13F76CC2-BB15-4FB8-8FDC-B458D5D558A1 Q40040813-65FD6F0F-C6E1-4483-B22B-D29143DB4202 Q40042419-CAF1E19F-6DB8-4DDA-9C9E-DB870D0CA063 Q40071705-F4B8864C-8AA0-4995-BCE0-5D8144C66F79 Q40339467-6323C066-19E2-426B-AF8B-5DFBEDFDFA0C Q40730039-A1DFAF49-9990-4698-830F-F935573F7F77 Q40748041-B7059A10-D81E-4CE9-8390-9562BD6C8898 Q41918753-4E8001A0-445F-4E33-B251-6C0F8158F98C Q42723888-10100F51-58BD-4A0C-BB71-0AECA73A0EBB Q47109778-7708D02C-4C38-4C8A-BEBB-3961663176C3 Q47110966-2BF93FA3-19AC-4232-AFAD-5F88302A8054 Q47112156-B17E2AD0-0864-4522-A52C-CF638F3D5ADB Q47215816-A06D638E-AA42-4426-996F-1EDDEAF78066 Q47604797-A59E43C5-7E8F-4EFA-B4B8-998D3D2663AD Q53692345-18BF5001-6BED-4CF0-AA4A-3E8A6DA5F365

P2860

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

http://www.wikidata.org/entity/Q35156935

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Balance of cellular and humora ...... caque models of HIV infection.

@ast

Balance of cellular and humora ...... caque models of HIV infection.

@en

type

label

Balance of cellular and humora ...... caque models of HIV infection.

@ast

Balance of cellular and humora ...... caque models of HIV infection.

@en

prefLabel

Balance of cellular and humora ...... caque models of HIV infection.

@ast

Balance of cellular and humora ...... caque models of HIV infection.

@en

P1433

Q35156935-E84EE30A-ECE3-4381-BB1E-0FE48DF8EB51

P1476

Q35156935-92DB1BA7-7C80-4BB8-8A86-60CC2A11A133

P2093

Q35156935-06B800FF-A639-47BB-BB9C-453353EF856F

Q35156935-10202848-43B0-4ABF-B13A-5BE1F06A1E12

Q35156935-1CEA0468-5F00-47BC-8CE2-B31F6D6617B0

Q35156935-24D7133A-1232-4C13-ABA2-DF30F437F5A2

Q35156935-38F0BAD9-5A9F-48DA-9194-68115AAEC942

Q35156935-3E09F3FA-1276-4618-AF46-18EAD0ABB260

Q35156935-409C34E0-0ED3-406F-B01C-7ED4523CADBE

Q35156935-424FB197-2810-4252-9954-3FBB4643EB79

Q35156935-47184074-830D-4E0C-AB4A-03A74BD45D27

Q35156935-486FEBE1-3ACA-4604-B53C-EB4CDF457DA4

P2860

Q35156935-021CAFD4-66E0-4671-9EBB-9EBE201F3DE1

Q35156935-048A4CC9-7053-4602-BBCB-85C4D9BDFA94

Q35156935-0E78ED08-BB64-4736-A989-B4896C436731

Q35156935-10C27BA3-CB75-4AE7-AD01-042B83AF8EB6

Q35156935-150CDF69-ABB0-4981-9372-F4B7B19C215D

Q35156935-159E8571-9E04-4D91-8BD1-3A34B3C8DC7C

Q35156935-1A91A63A-A4F0-4F1B-9EB6-CC248CECA1EC

Q35156935-1BB6A268-D26E-4D89-A8B0-C1806229C0E7

Q35156935-1CABFE7D-527A-40A2-BA0B-95E69B2C462D

Q35156935-201CAE6F-BC0B-48D5-9B6C-CD5EC24B408F

P304

Q35156935-0311C209-B24C-497F-91A7-EF7E293DBE5B

P31

Q35156935-81C9032A-D112-4686-90C1-B40A4F52E1A6

P356

Q35156935-A4A42FE6-BF0E-4F5F-AF6F-0D163EAA30F0

P407

Q35156935-EFEC0DCA-758D-4893-949B-14DC51C5710F

P433

Q35156935-56FF3D35-0BA1-4E48-B51C-BA1878316B96

P478

Q35156935-A94C5634-94FF-468F-B102-16350CAABCAF

P50

Q35156935-3A8568C1-79B5-4FE6-894D-D3359031006F

Q35156935-3B792C3D-C1C7-463F-8E40-D7F693831BAB

Q35156935-5BD6B46D-6073-4CB7-A4D8-349107171BC3

Q35156935-9F60441D-510E-4477-92A5-9DC6EF11919B

Q35156935-AC4E3155-F085-4B38-9213-5654E7CE03E1

Q35156935-F6D326E9-7F96-4EA1-8D15-A8EE79350FF7

P577

Q35156935-04111D72-E6AA-4991-BE1D-2067CEFA671C

P5875

Q35156935-10B8C779-0812-4596-AC92-EB5855B7D899

P698

Q35156935-6C0499DB-5DFE-4E5B-BB2C-C7DD4AA628F5

P932

Q35156935-A5760452-1C14-4427-B2BC-8027B4260D49

P356

PNAS.1423669112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Balance of cellular and humora ...... caque models of HIV infection.

@en

P2093

Anthony L DeVico

http://www.w3.org/2001/XMLSchema#string

Barbara K Felber

http://www.w3.org/2001/XMLSchema#string

Celia C LaBranche

http://www.w3.org/2001/XMLSchema#string

Daniel Zagury

http://www.w3.org/2001/XMLSchema#string

Genoveffa Franchini

http://www.w3.org/2001/XMLSchema#string

George K Lewis

http://www.w3.org/2001/XMLSchema#string

George N Pavlakis

http://www.w3.org/2001/XMLSchema#string

Hélène Le Buanec

http://www.w3.org/2001/XMLSchema#string

Ilia J Prado

http://www.w3.org/2001/XMLSchema#string

John H Eldridge

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

HIV-1 envelope glycoprotein structure

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

P304

E992-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1423669112

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Schwartz

Hélène Le Buanec

David C Montefiori

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273900348

http://www.w3.org/2001/XMLSchema#string

P698

25681373

http://www.w3.org/2001/XMLSchema#string

P932

4352796

http://www.w3.org/2001/XMLSchema#string